HIM
ANAB icon

Hillsdale Investment Management’s AnaptysBio ANAB Stock Holding History

Hillsdale Investment Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$256K Buy
+4,620
New +$249K 0.01% 542
2018
Q2 		– Sell
-900
Closed -$94K – 493
2018
Q1 		$94K Buy
+900
New +$101K 0.01% 289

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Hillsdale Investment Management's ANAB Position: Q1 2026 in Review

Hillsdale Investment Management opened a new position in AnaptysBio (ANAB) in Q1 2026: 4,620 shares worth $256K. The stake represents 0.01% of the portfolio and ranks #542 among its holdings. This is a return to the name: Hillsdale Investment Management previously reported a position in ANAB as recently as Q1 2018.

Hillsdale Investment Management first reported a position in ANAB in Q1 2018 and has held it in 2 quarters since. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • Hillsdale Investment Management held 4,620 shares of AnaptysBio worth $256K as of Q1 2026.
  • AnaptysBio was a new Hillsdale Investment Management position in Q1 2026.
  • AnaptysBio made up 0.01% of Hillsdale Investment Management's portfolio in Q1 2026, its #542 holding.
  • Hillsdale Investment Management first reported a position in AnaptysBio in Q1 2018 and has held it in 2 quarters since.
  • 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.